DOCSLIB.ORG

The Ebola Research Database Hosted by in Collaboration with The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Ebola Research Database www.ukcds.org.uk/resources/ebola-research-database Hosted by in collaboration with the Country/ Regional Funding Organisation/s Funding Start date and Value Title Type of study Type of Recipient Organisation Lay abstract Study sites Timelines (e.g. time to next phase) Link funder scheme* duration intervention Study the safety and efficacy of Favipiravir, an Institut National de la Sante et antiviral already licensed for influenza, first in an http://europa.eu/rapid/press- Europe European Commission Horizon 2020 € 2,575,810 REACTION Pre-clinical / Clinical Therapeutics de la Recherche Medicale 6 months until initial results expected animal model of the disease and then on patients release_IP-14-1194_en.htm (INSERM) (France) with Ebola virus disease. Research on interactions between the Ebola virus and the host. This will provide urgently needed answers regarding the pathophysiology and Bernhard-Nocht-Institut fuer http://europa.eu/rapid/press- Europe European Commission Horizon 2020 € 1,759,326 EVIDENT Clinical Trial transmissibility of the disease, and will help better Tropenmedizin (Germany) release_IP-14-1194_en.htm guide the planned clinical trials on vaccines and potential treatments, as well as the management of patients with Ebola virus disease. Study the safety and efficacy of using antibodies Institut de Recherche pour le produced in horses against Ebola, as a passive http://europa.eu/rapid/press- Europe European Commission Horizon 2020 € 1,992,770 IF-EBOla Basic science/ Pre-clinical Therapeutics Developpement (France) immunity treatment for patients with Ebola virus release_IP-14-1194_en.htm disease. NIAID is supporting Crucell’s development of a J&J (Crucell), New Brunswick, multivalent Ebola/Marburg vaccine using Multivalent Ebola/Marburg NJ in collaboration with recombinant adenovirus vector platforms and US NIH/NIAID Pre-clinical/ Clinical Trial Vaccine Phase I site TBD A Phase I clinical trial is planned for late 2015. vaccine Bavarian Nordic - Kvistgaard, Bavarian Nordic’s MVA (modified vaccinia Ankara) DK vectored Ebola vaccine which will be used in a prime-boost strategy NIAID's Laboratory of Infectious Diseases Thomas Jefferson University and intramural NIAID, in collaboration with DoD, is supporting http://www.niaid.nih.gov/topics/ebola US NIH/NIAID Rabies/Ebola vaccine Pre-clinical Vaccine (Bethesda, MD) and Thomas investigators are developing a vaccine candidate on TBD development and GMP manufacture of the Marburg/Pages/rabiesVaccEbola.asp Jefferson University, the licensed rabies virus vaccine backbone. vaccine. Results sometime in 2015. x. (Philadelphia, PA) In vitro - More than 30 different therapeutic Therapeutics – selected candidates with different formulations/regimens are Various academic and for US NIH/NIAID preclinical in vitro studies Pre-clinical Therapeutics being evaluated, including cysteine-protease Candidates still in development or preclinical. profit entities (various candidates) inhibitors, polymerase inhibitors, kinase inhibitors, and monoclonal antibody cocktails In vivo - A novel drug (nucleoside analogue) that NHP studies ongoing - Results expected end US NIH/NIAID BCX4430 Therapeutic Pre-clinical Therapeutics BioCryst Pharmaceutical TBD interferes with the reproductive process of the virus of 2014. Limited in vitro data against Ebola. Recently administered under emergency IND in the In vivo - A broad-spectrum antiviral derivative of US NIH/NIAID CMX-001, Brincidofovir Pre-clinical Therapeutics Chimerix, Inc. TBD U.S. NIAID supporting in vivo testing against cidofovir. Limited in vitro data against Ebola. Ebola. In clinical development for other viral diseases. Phase I already completed. The aim of this project is the preclinical development and characterisation new vaccines against Ebola virus infections, based on recombinant vaccinia viruses MVA. There are currently two promising candidate vaccines against the Ebola virus available, which are yet to be tested in humans. Clinical trial preparations are underway Developing MVA and an implementation is expected at the beginning http://www.dzif.de/en/news_press/ne Federal Ministry of Education (Combined budget vector vaccines to of 2015. These vaccines are either effective against ws_press_releases/view/detail/artikel/ Germany EBOKON Pre-clinical Vaccine Institute for Infection Medicine and Zoonoses, LMU Munich Clinical trials anticipated for early 2015. and Research (BMBF) of €2.3million) prevent Ebola virus two subtypes of the Ebola virus (adenovirus-based ebokon_strengthening_ebola_researc infections vaccine), or monovalently effective against the h/ Zaire Ebola virus only (VSV-based vaccine). However, there are currently three independent virus outbreaks in Africa, highlighting the need for multivalent Ebola vaccines. The project will contribute to developing broad and specific Ebola virus vaccines which can quickly be drawn upon for testing in clinical settings. The antibody cocktail (ZMAPP) seems to cause significant improvement in some people with Ebola infections. However, the cocktail is globally no longer available and the production of a few new http://www.dzif.de/en/news_press/ne Developing and Federal Ministry of Education (Combined budget doses takes months. There is currently a lack of ws_press_releases/view/detail/artikel/ Germany EBOKON validating pan-Ebola Pre-clinical Therapeutics Paul-Ehrlich Institut, Langen and Research (BMBF) of €2.3million) concepts for rapidly developing and producing ebokon_strengthening_ebola_researc vaccination strategies passive immune therapies. This project compares h/ different vaccination strategies and validates the most promising ones with further experiments in Marburg. Basic and Pre-clinical Country/ Regional Funding Organisation/s Funding Start date and Value Title Type of study Type of Recipient Organisation Lay abstract Study sites Timelines (e.g. time to next phase) Link funder scheme* duration intervention There are currently no antiviral drugs available against Ebola viruses. One potential mechanism of anti-Ebola virus therapy could be to inhibit its entry http://www.dzif.de/en/news_press/ne Analysing and inhibiting into target cells. Ebola viruses contain glycoprotein Federal Ministry of Education (Combined budget ws_press_releases/view/detail/artikel/ Germany EBOKON Ebola virus entry into host Basic science/ Pre-clinical Therapeutics German Primate Centre, GöttingenGP, a substance which mediates their entry into and Research (BMBF) of €2.3million) ebokon_strengthening_ebola_researc cells host cells. In order to identify potentially highly h/ effective antiviral drugs, this project will investigate the interaction between the virus and host cells and how it can be inhibited. Immune responses to Ebola viruses are not well understood because insufficient numbers of patient samples have been available up to now. For Using chimeric mouse example, it is not known how the T cell response of http://www.dzif.de/en/news_press/ne Federal Ministry of Education (Combined budget models to investigate patients who survive Ebola infections differs to ws_press_releases/view/detail/artikel/ Germany EBOKON Basic science Bernhard Nocht Institute for Tropical Medicine, Hamburg and Research (BMBF) of €2.3million) Ebola virus immunity and immune responses in cases where infection was ebokon_strengthening_ebola_researc pathogenesis fatal. Mouse models in which the virus can replicate h/ will be used to help investigate these questions. This project is in collaboration with the Heinrich Pette Institute in Hamburg. ebola viruses (EBOVs) are NIAID category A priority pathogens that cause severe viral hemorrhagic fever. A critical research task is to define how the molecular interactions between A novel inhibitor of http://projectreporter.nih.gov/project_i 01/12/2014, 12 ICAHN School of Medicine at filoviruses and the human host trigger life- US NIH/NIAID $432,835 interferon and oxidative Basic science nfo_description.cfm?aid=8769134&ic month duration Mount Sinai threatening infections. Defining such interactions will stress signalling shed light on the triggers of viral hemorrhagic fever de=23418087 and will facilitate prophylactic and therapeutic interventions for this frequently lethal syndrome. We hypothesize that evasion of host innate defenses, ebolaparticularly viruses interferon are among (IFN)-??? the most responses, lethal human is critical pathogens with mortality rates approaching 90% for the Zaire subtype. They are also a potential bioterrorism agent. ebola virus infection causes a Interactions of Ebola virus http://projectreporter.nih.gov/project_i 1/05/2010, 5 year severe hemorrhagic disease in humans for which US NIH/NIAID $410,485 glycoproteins with host Basic science University of Pennsylvania nfo_description.cfm?aid=8653523&ic duration there are no therapeutic treatments nor protective cells vaccines currently available. For these de=23418087 reasons, ebola virus is classified as a "category A priority pathogen" by NIH. Expressed on the virus and infected cell surface, the ebolaglycoproteins Wefacilitate reviewed entry availableof the virus epidemiologic, into host cells clinical, and also and laboratory records of patients in whom EVD was diagnosed between May 25 and June 18, 2014. The incubation period and case fatality rate among Protective and Pathogenic patients with EVD in Sierra Leone are similar to B Cell Epitope August 2009; 6 http://www.nejm.org/doi/full/10.1056/N US NIH/NIAID B Cell Epitopes in human Pre-clinical Tulane University those
Recommended publications
  • What You Need to Know About Rabies

    What You Need to Know About Rabies

    WHAT YOU NEED TO KNOW ABOUT RABIES ASSOCIATION OF IMMUNIZATION MANAGERS FEBRUARY 2021 Bavarian Nordic is a fully integrated, leading biotechnology company focused on the research, development, innovation, manufacturing and commercialization of vaccines for the prevention and treatment of life-threatening diseases 1 VIRAL DISEASE ALMOST ALWAYS FATAL IF UNTREATED Paralytic rabies Ascending spread of flaccid Classical (furious) rabies Onset of coma DEATH muscle weakness, bilateral Hyper-excitability, periods weakness of facial muscles, of confusion, hallucinations, sphincter involvement agitation and hydrophobia Coma (0–14 days) Acute neurological phase (2–7 days) Nonspecific symptoms Fever, malaise, chills, fatigue, First neurological signs insomnia, anorexia, headache, (>10 days) anxiety, irritability Prodromal phase (2–10 days) Exposure Bite or scratch from, or Incubation of virus mucosal contact with, (20–90 days) a rabid animal 1. Jackson et al. In Rabies (2nd edition). Chapter 7. 2007: 309–340; 2. WHO. Wkly Epidemiol Rec 2018; 93: 201–20; 3. Hemachudha et al. Lancet Neurol 2002;1:101–9; 4. WHO. Rabies: Fact Sheet. https://www.who.int/en/news-room/fact-sheets/Detail/rabies [accesseD July 2020]. PREVALENCE IN THE USA Rabies transmission in dogs has been virtually eliminated in the USA, in part due to widespread canine vaccination programs5 • As a result, wildlife has accounted for >90% of rabid animals reported in the USA since 19805-7 • Primary vectors in this region are skunks, foxes, raccoons, bats and mongooses (in Puerto Rico)5-7 • In the US, the primary rabies vector is the bat due to encounters with bats that may be less recognized e.g.
  • T. Franklin Williams Scholars Program

    T. Franklin Williams Scholars Program

    Developing a New Generation of Medical Subspecialists with Expertise in Aging and Care of the Elderly T. Franklin Williams Scholars Program Report to T. Franklin Williams Scholars Program Evaluation Team ASP Geriatrics Steering Committee Integrating Geriatrics Project Evaluation Team May 2011 Submitted by: Erika D. Tarver Project Administrator Association of Specialty Professors 330 John Carlyle Road Suite 610 Alexandria, VA 22314 T: (703) 341-4540 F: (703) 519-1890 [email protected] Kevin P. High, MD Principal Investigator William R. Hazzard, MD Co-Principal Investigator Table of Contents Narrative Progress Report Application and Award Progress Summary of Success of T. Williams Scholars Program Appendices A. 2008 Scholars 24-Month Progress Reports Neena S. Abraham, MD (Note: This is Dr. Abraham’s final report) Steven G. Coca, DO Jeffrey G. Horowitz, MD Danelle F. James, MD Heidi Klepin, MD George C. Wang, MD 2009 Williams Scholars Progress Reports and Summary of 18-Month Questionnaire B. Peter Abadir, MD 12-month Progress Report C. Kathleen M. Akgun, MD 12-Month Progress Report Publication D. Alison Huang, MD 12-Month Progress Report Publication E. Eswar Krishnan, MD 12-Month Progress Report Publication F. Rohit Loomba, MD Publication G. Sharmilee Nyenhuis, MD 12-Month Progress Report Publication H. Peter P. Reese, MD 12-Month Progress Report Publication I. Erik B. Schelbert, MD 12-Month Progress Report Publication J. Helen Keipp Talbot, MD 12-Month Progress Report Publication K. Summary of 18-Month Questionnaire 2010 Williams Scholars Mentor Interviews and Summary of Six-Month Questionnaire L. Kellie Hunter-Campbell, MD Six-Month Mentor Interview M.
  • Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership

    Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership

    VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership Saint-Herblain, France, June 18, 2020 – Valneva SE, (“Valneva”), a specialty vaccine company, and Bavarian Nordic A/S (OMX: BAVA) today announced that they have signed a binding term sheet to establish a partnership for the marketing and distribution of their commercial products. The partnership will provide both companies with additional critical mass, significant commercial synergies and a market leadership position in the specialty vaccine industry. Under the agreed terms, Valneva will commercialize Bavarian Nordic’s marketed vaccines leveraging its commercial infrastructure in Canada, UK, France and Austria. Valneva will also take responsibility for Belgium and the Netherlands where it will set up new commercial operations. Bavarian Nordic will commercialize Valneva’s marketed products in Germany and Switzerland. The partnership includes vaccines that protect against rabies, Japanese Encephalitis, tick-borne encephalitis and cholera. The agreement follows Bavarian Nordic’s recent acquisition of two commercial vaccines from GlaxoSmithKline. The transition from current arrangements will commence later this year and through 2021 in line with existing distribution agreements. Valneva expects limited additional revenues in 2020 with more material impact from 2021 onwards. Thomas Lingelbach, CEO of Valneva, commented, “We are excited to join forces with Bavarian Nordic to continue to build our commercial business and to enhance our product offering to our customers. This partnership provides excellent synergy for both companies as well as greater breadth in our commercial portfolios.” Paul Chaplin, President & CEO of Bavarian Nordic, added, “We are pleased to collaborate with Valneva in the ongoing commercialization of our business.
  • Written Statement for Dr. Anthony Fauci, Director, NIAID

    Written Statement for Dr. Anthony Fauci, Director, NIAID

    DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH The Role of the National Institute of Allergy and Infectious Diseases Research in Addressing Ebola Virus Disease Testimony before the House Foreign Affairs Committee Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations Anthony S. Fauci, M.D. Director National Institute of Allergy and Infectious Diseases September 17, 2014 Mr. Chairman and Members of the Committee: Thank you for the opportunity to discuss the National Institutes of Health (NIH) response to the global health emergency of Ebola virus disease. I direct the National Institute of Allergy and Infectious Diseases (NIAID), the lead institute of the NIH for conducting and supporting research on infectious diseases, including viral hemorrhagic fevers such as those caused by Ebola virus infection. For over six decades, NIAID has made important contributions to advancing the understanding of infectious, immunologic, and allergic diseases, from basic research on mechanisms of disease to applied research to develop diagnostics, therapeutics, and vaccines. NIAID has a dual mandate that balances research addressing current biomedical challenges with the capacity to respond quickly to newly emerging and re-emerging infectious diseases, including bioterror threats. Critical to these efforts are NIAID’s partnerships with academia and pharmaceutical companies, and collaborations with other federal entities, particularly the Centers for Disease Control and Prevention, the Food and Drug Administration (FDA), the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense. OVERVIEW OF EBOLA VIRUS DISEASE Viral hemorrhagic fevers are severe illnesses that can be fatal and are caused by a diverse group of viruses including Marburg virus, Lassa virus, and Ebola virus.
  • Journal Pre-Proof

    Journal Pre-Proof

    Journal Pre-proof Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. Jaworski PII: S2319-4170(20)30209-2 DOI: https://doi.org/10.1016/j.bj.2020.11.011 Reference: BJ 374 To appear in: Biomedical Journal Received Date: 2 September 2020 Revised Date: 6 November 2020 Accepted Date: 22 November 2020 Please cite this article as: Jaworski JP, Neutralizing monoclonal antibodies for COVID-19 treatment and prevention, Biomedical Journal, https://doi.org/10.1016/j.bj.2020.11.011. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Chang Gung University. Publishing services by Elsevier B.V. TITLE: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. JAWORSKI Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina KEYWORDS: SARS-CoV-2, Coronavirus, Monoclonal Antibody, mAb, Prophylaxis, Treatment CORRESPONDING AUTHOR: Dr. Juan Pablo Jaworski, DVM, MSc, PhD. Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria Las Cabañas y de los Reseros (S/N), Hurlingham (1686), Buenos Aires, Argentina Tel / Fax: 054-11-4621-1447 (int:3400) [email protected] ABSTRACT The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
  • Bavarian Nordic Annual Report 2018 Management Commentary | Financial Statements

    Bavarian Nordic Annual Report 2018 Management Commentary | Financial Statements

    Unlocking the power of the ANNUAL immune system REPORT 2018 199425 2019 YEARS OF GREAT ACHIEVEMENTS IN THE VACCINE SPACE STIMULATING THE IMMUNE SYSTEM GIVING HOPE TO MILLIONS Management commentary | Financial statements CONTENTS MANAGEMENT FINANCIAL COMMENTARY STATEMENTS INTRODUCTION BUSINESS AND PIPELINE CONSOLIDATED FINANCIAL STATEMENTS Letter from the CEO & chairman .................... 4 Product pipeline.................................. 20 Consolidated income statements .................. 68 At a glance ....................................... 6 Infectious disease ................................ 22 Consolidated statements of comprehensive 25 years of great achievements .................... 8 Our partnership with Janssen ...................... 28 income .......................................... 68 Key developments................................ 10 Cancer immunotherapy ........................... 36 Consolidated statements of cash flow.............. 69 A word from the new CFO......................... 12 Chordoma........................................ 38 Consolidated statements of financial position Strategy track ................................... .16 – assets ......................................... 70 Financial results for 2018 ......................... .18 CORPORATE INFORMATION Consolidated statements of financial position The Bavarian Nordic share ........................ .46 – equity/liabilities ............................... 71 Corporate social responsibility .................... .48 Consolidated statements of changes in
  • CP-162837 Johnson & Johnson Announces European Commission

    CP-162837 Johnson & Johnson Announces European Commission

    News Release Media Contacts: Seema Kumar +1 908-405-1144 [email protected] Sarah Smith +44 7920 082012 [email protected] Investor Relations: Jennifer McIntyre +1 732-524-3922 Chris DelOrefice +1 732-524-2955 Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine This marks the first major regulatory approval of a vaccine developed by Janssen The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19 NEW BRUNSWICK, N.J., 1 July 2020 – Johnson & Johnson today announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen for the prevention of Ebola Virus Disease. Enabled by this approval, Janssen is now collaborating with the World Health Organization (WHO) on vaccine pre-qualification, which should help accelerate registration of its preventive Ebola vaccine regimen in African countries and facilitate broader access to those most in need. Two Marketing Authorisation Applications (MAAs) were submitted to the European Medicines Agency (EMA) for the vaccines composing the two-dose regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo). Marketing Authorisation under exceptional circumstances has been granted following Accelerated Assessment of the MAAs and a positive opinion by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Janssen’s Ebola vaccine regimen is indicated for active immunization for the prevention of Ebola Virus Disease caused by the Zaire ebolavirus species in individuals aged one year and above.
  • HIV?AIDS Researchers at the NIH Clinical Center

    HIV?AIDS Researchers at the NIH Clinical Center

    The NIH Clinical Center treats a diverse group of patients from all over the world. It also draws researchers from different cultures and backgrounds. Learn more about some of the many researchers who conduct their work on the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the Clinical Center. Thomas C. Quinn, M.D., M.Sc., conducts research for the National Institute of Allergy and Infectious Diseases at the NIH Clinical Center. He is a senior investigator and chief of the International HIV/STD Section of the Laboratory of Immunoregulation. Dr. Quinn obtained his M.D. from Northwestern University. He was a research associate in infectious diseases in the NIAID Laboratory of Parasitic Diseases and completed a fellowship in infectious diseases at the University of Washington. Since 1981, he has been assigned to the division of infectious diseases at Johns Hopkins University, where he became a professor of medicine in 1991. Dr. Quinn is a member of the Institute of Medicine and the National Academy of Sciences and is a fellow of the American Association for the Advancement of Science. His major areas of research are: Definition of epidemiologic features of HIV-1 and HIV-2 infections in developing countries and the United States Assessment of biomedical interventions to control HIV, including circumcision, prevention of mother-to-child transmission, pre-exposure prophylaxis, and vaccine development Assessment of the frequency of Chlamydia trachomatis infections in selected populations using noninvasive sensitive nucleic-acid amplification assays for diagnosis Evaluations of interventions to control blinding trachoma due to Chlamydia trachomatis in sub-Saharan Africa See the full program description.
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The

    That Record-Breaking Sprint to Create a COVID-19 Vaccine The

    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
  • Nci-Plan-2013.Pdf

    Nci-Plan-2013.Pdf

    THE NATIONAL CANCER PROGRAM MANAGING THE NATION’S RESEARCH PORTFOLIO AN ANNUAL PLAN AND BUDGET PROPOSAL FOR FISCAL YEAR 2013 National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Contents 1 Foreword 4 Provocative Questions 8 Center for Cancer Genomics 16 Introduction to Cancer Profiles 18 Pancreatic Ductal Adenocarcinoma 22 Colorectal Cancer 26 B-Cell Lymphoma 30 Renal Cell (Kidney) Cancer 34 GI Stromal Cancer 39 Research Focus: Comorbidities 42 Research Focus: Circulating Tumor Cells 44 Research Focus: Reducing Cancer Health Disparities 50 The Frederick National Laboratory for Cancer Research 61 Small Business Innovation Research, Small BusinessTechnology Transfer (SBIR, STTR) 66 NCI Center for Global Health 72 NCI-Designated Cancer Centers 83 Glossary of Terms 84 Budget FOREWORD The National Cancer Program MANAGING THE NATION’S RESEARCH PORTFOLIO his year marks the 75th anniversary of the founding of the National Cancer Institute, the first so-called “categorical institute” of what has become the National Institutes of Health, with its 27 Institutes and Centers. Over the years, the Congress and the public have generously supported the TNCI—and the NIH generally—with sustained budgetary increases. This was especially true for the NCI during the rapid expansion of its budget following the National Cancer Act of 1971 and for the NIH, including the NCI, during the 5-year doubling of its budget, launched in 1998. Both of these eras of rapid growth were remarkably fruitful. The first launched the pursuit of cancer genes and the molecular basis of oncogenesis, laying the foundation for the transformation of clinical oncology that is now occurring.
  • NIHAA Update 1Velco111es Lerters and Eastern Europe and at the Undergradu­ 1968, a Period of Considerable Growth News from Its Readers

    NIHAA Update 1Velco111es Lerters and Eastern Europe and at the Undergradu­ 1968, a Period of Considerable Growth News from Its Readers

    The Newsletter of the L NIH Alumni Association Summer 1999 Vol. 11, No. 2 date NIHAA Members Enjoy June Annual Meeting with Henney, Morella Alumni attendi ng the 1999 annual meeting of the NIH.AA were given a first-band briefing on FDA by Dr. Jane E. Henney, the receml y appointed FDA commissioner. Tbe audience also participated in a question and answer exchange witb Rep. Constance A. Morella (R-Md.), who was presented with tbe NIHAA 1999 Public Service Award. Almost I00 alumni attended the June 12 morning meeting at the Mary Woodard Lasker Center on the NIH campus. Henney, wbo was NCI deputy director for five of her lO years at NIH (1985-1995) spoke infonnalJy on some of FDA's principal concerns at this time: the agency's efforts to speed Shown at the NIHAA annual meeting are (from I} NIH alumna Dr. Jane E. Henney, FDA up review without sacrifice of quality commissioner, who spoke on "Back Home Again via Indiana, Kansas and New Mexico," and safeguards; tbe need for recruiting Dr. John F. Sherman, Rep. Constance A. Morella (R-Md.), who received the 1999 NIHAA Public Service Award, and Dr. William S. Jordan, Jr., outgoing NIHAA president. (see A flflual Meeting, p. 12) Director's Advisors Bat 6 for 7 in June Meeting In This Issue Page Choppin To Give Third Research Festival '99 J By Rich McManus NIHAA Shannon Lecture Ca/e11dar 5 The scorecard at the end of a daylong Dr. Purnell W. Cboppin, president of .News .from a11d about Nlf/A;/ me111be1:r (f session of lhe advisory committee to the Howard Hughes Medical lnstirure, the NIH director (ACD) on June 3 read A le11erjro1111he 11e111 Nlf/AIJ preside111 IO will deliver the third James A.
  • Johnson & Johnson Joins World Health Organization in Efforts To

    Johnson & Johnson Joins World Health Organization in Efforts To

    Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa May 13, 2021 Up to 200,000 Johnson & Johnson Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone Company's Ebola vaccine regimen also receives Prequalification from the WHO The Johnson & Johnson vaccine regimen is designed to be used proactively to induce immunity against Ebola in adults and children NEW BRUNSWICK, N.J., May 13, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the World Health Organization (WHO) and the government of Sierra Leone have begun administering the Company's Ebola vaccine regimen as part of a WHO early access clinical program aimed at preventing further spread of Ebola in West Africa. The vaccine regimen, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in collaboration with Bavarian Nordic A/S, is being donated to the WHO by Janssen for the purposes of the early access clinical program. Johnson & Johnson also announced that its Ebola vaccine regimen has received Prequalification from the WHO, which will help accelerate its registration in countries where Ebola is a persistent public health threat and facilitate broader access to people at risk of exposure to this virus. Health authorities in Guinea officially declared a new Ebola outbreak in February 2021 after the West African country experienced its first cases of disease since the end of the 2014-2016 Ebola outbreak – which was the worst on record. Preliminary data obtained through genetic sequencing suggest that the new outbreak was caused by the same virus strain also responsible for the 2014-2016 outbreak and was likely reintroduced by a survivor.